TY - JOUR
T1 - Visual function improvement in patients with macroprolactinomas treated with bromocriptine
AU - Lesser, R. L.
AU - Zheutlin, J. D.
AU - Boghen, D.
AU - Odel, J. G.
AU - Robbins, R. J.
PY - 1990
Y1 - 1990
N2 - We studied eight patients who had visual field defects secondary to prolactin-secreting macroadenomas and who had improved visual function with bromocriptine treatment without surgery or radiation. We recommend bromocriptine as a primary treatment for prolactin-secreting macroadenomas. If therapy is effective, continued regular neuro-ophthalmologic, endocrine, and imaging studies are necessary, because treatment with bromocriptine must be continued indefinitely.
AB - We studied eight patients who had visual field defects secondary to prolactin-secreting macroadenomas and who had improved visual function with bromocriptine treatment without surgery or radiation. We recommend bromocriptine as a primary treatment for prolactin-secreting macroadenomas. If therapy is effective, continued regular neuro-ophthalmologic, endocrine, and imaging studies are necessary, because treatment with bromocriptine must be continued indefinitely.
UR - http://www.scopus.com/inward/record.url?scp=0025278852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025278852&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(14)70683-X
DO - 10.1016/S0002-9394(14)70683-X
M3 - Article
C2 - 2333917
AN - SCOPUS:0025278852
VL - 109
SP - 535
EP - 543
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 5
ER -